Substance / Medication

Phenytoin sodium

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

91 trials linked to this intervention

91
Total Trials
16
Recruiting
33
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers.
Inoue Yushi, Usui Naotaka, Hiroki Tadayuki et al. · Eur J Drug Metab Pharmacokinet · 2013
PMID: 22968854RCTFull text (PMC)
Relative bioavailability of orally administered fosphenytoin sodium injection compared with phenytoin sodium injection in healthy volunteers.
Kaucher Kevin A, Acquisto Nicole M, Rao Gauri G et al. · Pharmacotherapy · 2015
PMID: 26011141Observational
Reversible lesion involving the splenium of the corpus callosum caused by phenytoin sodium withdrawal.
Wang Lingling, Wang Xiaoshan, Shi Xiangsong et al. · Neurol Sci · 2017
PMID: 27866281Case Report
Jiedu tongbi tang plus phenytoin sodium for severe acute sciatica.
Wang Dechang · J Tradit Chin Med · 2003
PMID: 14719291Case Report
USE OF SINGLE HIGH DOSE OF PHENYTOIN SODIUM FOR MANAGEMENT OF A CASE OF ECLAMPSIA.
Kaul K K · Med J Armed Forces India · 2000
PMID: 28790766Case ReportFull text (PMC)
A falsely elevated blood alcohol concentration (BAC) related to an intravenous administration of phenytoin sodium.
Leuger Laurent, Abbara Chadi, Baudriller Antoine et al. · Clin Chem Lab Med · 2025
PMID: 38905355Other
Investigation on the phenytoin sodium channel-blocker effect in PDT of MDA MB 231 breast cancer using a positively charged PS.
Esfahani HomaSadat, Hosseinzadeh Reza, Khorsandi Khatereh · Sci Rep · 2025
PMID: 40592969OtherFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Phenytoin sodium (substance)
SNOMED CT
387416005
UMLS CUI
C0237417

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
91
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.